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Abstract:  ROSE, J. M. AND K. L. AUDUS.  Receptor-mediated angiotensin II transcytosis by brain 
microvessel endothelial cells.  PEPTIDES __( ) _____, 199_. - Angiotensin II (Ang II) uptake and transport 
across monolayers of bovine brain microvessel endothelial cells (BMECs) was demonstrated.  Ang II 
transport was linear up to 2 hours, saturable with a Km of 1.7 nM, and tended to be polarized with the 
apical-to-basolateral transport being greater.  [3H]-Ang II transport was found to be inhibited by excess 
unlabeled Ang II, by the Ang II analog sarathrin, and by the endocytic inhibitor phenylarsine oxide.  Ang 
II-(2-8) and -(3-8) were shown to significantly increase the transport of Ang II.  These results 
demonstrate for the first time the receptor-mediated transcytosis of Ang II across brain microvessel 
endothelium. 
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INTRODUCTION 
 The effective delivery of therapeutic peptides out of the blood to specific extravascular targets 
remains a major obstacle in the use of these agents in the treatment of disease and underscores the 
need for understanding the fundamental mechanisms by which macromolecules distribute into and 
across tissue barriers.  Due to the unique properties of the endothelium lining the microvasculature of 
the brain in particular, the potential treatment of central nervous system disorders with peptides 
presents a significant challenge (5).  This thin, continuous nonfenestrated endothelium with tight 
intercellular junctions is referred to as the blood-brain barrier (BBB) (5,8,24).  Along with tight junctions, 
the cells also have few pinocytic vesicles, a complex glycocalyx, and significant metabolic capacity.  
These characteristics make the BBB a very selective layer that excludes most water-soluble substances, 
including peptides, from entering the central nervous system from the blood (3,5). 
 Angiotensin II (Ang II) is an endogenous octapeptide that produces a number of physiological 
actions as a potent vasoconstrictor, stimulator of the release of cardiovascular regulators (e.g., 
endothelin and prostaglandins), neurotransmitter, and vascular cell growth promoter (22,25,38).  A 
recent study indicates that Ang II triggers internalization-recycling processes that seem to be a 
fundamental part of the Ang II type AT1 receptor transduction mechanism (26).   In addition, receptor-
mediated endocytosis of Ang II itself occurs in a number of different cell types (6,17,19,34,36) and does 
undergo transcytosis across peripheral endothelial cells (18).  Moreover, the in vivo demonstration of 
receptor-mediated uptake of Ang II by endothelial cells has prompted a hypothesis that internalization 
of Ang II is a physiological mechanism for clearance and protection of the peptide from endothelial 
peptidases (35).    
Previous work in our laboratory established that Ang II has specific binding sites on primary 
cultures of  bovine brain microvessel endothelial cells (BMECs).  Ang II also has typical biological effects 
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in BMECs including permeability regulation and control of cell growth (11-13).  We have demonstrated 
the expression of AT1 receptors on BMECs and that uptake and passage of Ang II across these cells can 
be blocked by the AT1 antagonist, losartan, but not an AT2 antagonist (27).   Moreover, it appears that 
Ang II remains intact on uptake and transcellular processing by BMECs (2,12,28).  On the basis of this 
background, the objective of this study was to develop evidence as to whether the transport of Ang II 
across BMEC monolayers was due to a receptor-mediated transcytotic process.  This information adds to 
the pharmaceutical field’s knowledge base on transport mechanisms perhaps applicable to the design of 
future therapeutic peptides and their delivery into the central nervous system, and contributes to our 
fundamental understanding of the mechanisms regulating vascular levels of peptide hormones. 
 
METHODS 
Chemicals 
 [3H]-Angiotensin II ([3H]-Ang II), specific activity 45 Ci/mmol, was purchased from Amersham 
(Arlington Heights, IL).  Unlabeled Ang II, Ang II-(1-7), Ang II-(2-8), Ang II-(3-8), and sarathrin, and 
endocytic inhibitors chloroquine, monensin, and phenylarsine oxide, were purchased from Sigma 
Chemical Company (St. Louis, MO).  All other compounds used were of the highest commercially 
available quality. 
 
Cell Culture 
 BMECs were isolated from gray matter of cerebral cortices by enzymatic digestion and 
subsequent centrifugation, and seeded into primary culture as detailed by Audus et al. (4).  This method 
has been previously characterized as reported in literature (4,7).  Isolated BMECs were seeded at a 
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density of 50,000 cells/cm2 into culture plates or 100 mm culture dishes (Corning Costar Corporation, 
Cambridge, MA) that were precoated with rat-tail collagen and bovine fibronectin (Sigma Chemical Co.).  
The culture medium consisted of 45 % minimum essential medium, 45 % F-12 Ham nutrient mixture 
(Gibco Life Technologies, Grand Island, NY), 10 mM HEPES, pH 7.4, 13 mM sodium bicarbonate, 10 % 
platelet-depleted equine serum, 100 µg/ml heparin, 100 µg/ml streptomycin, 100 µg/ml penicillin G, 50 
µg/ml polymyxin B, and 2.5 µg/ml amphotericin B (Sigma Chemical Co.).  The cells were cultured at 37°C 
with 95 % humidity and 5 % CO2.  Cells were fed on the third day after seeding and then every other day 
until confluent monolayers were formed (10-14 days). 
 
Angiotensin II Internalization 
 Total Ang II binding and uptake was studied at 37°C using confluent monolayers grown in 12-
well plates.  A pulse of [3H]-Ang II dissolved in culture medium containing serum was added to each well 
at selected times between 15 minutes and 2 hours.  At the conclusion of the experiment, the medium 
was aspirated from each well and the wells were rinsed three times with 4°C culture medium.  The cell 
monolayers were solubilized by the addition of 1.0 ml of 0.2 N NaOH / Triton X-100.  The lysate was 
collected, placed in a scintillation vial with 10 ml of scintillation cocktail, and assayed with a Beckman LS 
6800 scintillation counter.  To obtain the amount of internalized Ang II, the uptake of the peptide by 
BMECs at 4°C, a temperature at which only binding occurred (12), was determined as above and 
subtracted from the 37°C data. 
 
Angiotensin II Transendothelial Permeability 
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 Polycarbonate membranes (13 mm diameter; pore size 0.4 µm) were placed into 100 mm tissue 
culture dishes and coated with rat-tail collagen and bovine fibronectin.  BMECs were grown to confluent 
monolayers, as determined by inspection of the areas around the membranes using an inverted 
microscope.  The basolateral side of the cells was defined as the side facing the collagen matrix.  After 
confluent monolayers were formed, the membranes were placed in a horizontal Side-bi-Side™ diffusion 
apparatus (Crown Glass, Inc., Somerville, NJ) for transendothelial permeability studies.  The area of the 
diffusion membrane was 0.636 cm2.  The donor and receiver chambers were filled with 3.0 ml of culture 
medium and the temperature was maintained with an external circulating water bath.  The contents of 
each chamber were stirred with Teflon coated magnetic stir bars at a speed of 600 r/min driven by an 
external drive console (Crown Glass, Inc.). 
 The apical-to-basolateral permeation of [3H]-Ang II was studied for 2 hours at 4°C and 37°C 
across confluent monolayers and at 37°C across collagen-coated membranes.  The concentration-
dependence of permeation was studied by adding to each donor chamber an aliquot of unlabeled Ang II 
mixed with [3H]-Ang II.  An  aliquot of 25 µl was removed from the donor chamber to be assayed for 
initial donor concentration.  Sample aliquots of 100 µl were removed from the receiver chamber at 
various times and the volume was replaced with fresh culture medium.  The samples were placed in a 
scintillation vial with 10 ml of scintillation cocktail and assayed by scintillation spectrometry.  The flux 
was determined by plotting pmoles versus minutes. 
 The apical-to-basolateral and the basolateral-to-apical permeation of 3 nM [3H]-Ang II was 
studied at 37°C.  Samples were taken as described above.  The flux was determined by plotting pmoles 
Ang II appearing in the receiver chamber versus minutes.  The apparent permeability coefficient was 
calculated using the equation: 
    P = Flux / (A*CDo) 
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where flux is the slope of the line, A is the area of the membrane, and CDo is the initial donor 
concentration (1).  The donor concentration did not change by more than 10 % during the time period of 
these experiments. 
 
Effect of Unlabeled Angiotensin II Peptides on [3H]-Angiotensin II Uptake and Transport 
 The effect of unlabeled Ang II, an Ang II peptide antagonist (sarathrin; [Sar1,Thr8]-Ang II), or Ang 
II peptide fragments (Ang II-(1-7); Ang II-(2-8) or Ang III; and Ang II-(3-8) or Ang IV) on the uptake of [3H]-
Ang II was studied on confluent BMEC monolayers grown in 12-well plates.  A pulse of [3H]-Ang II was 
added to each well along with nM concentrations of unlabeled peptides dissolved in culture medium 
containing serum.  The plates were incubated at 37°C for 45 minutes.  After the incubation, the 
monolayers were quickly rinsed three times with 4°C culture medium and solubilized as described 
above.  An aliquot of 100 µl of lysate was removed to analyze protein content with the BCA protein 
assay kit (Pierce, Rockford, IL).  The remaining lysate from each well was collected, placed in a 
scintillation vial with 10 ml of scintillation cocktail, and assayed with a Beckman LS 6800 scintillation 
counter. 
 The effect of nM concentrations of unlabeled Ang II, sarathrin, Ang II-(1-7); Ang  III and Ang IV on 
the transport of a pulse of [3H]-Ang II was  studied at 37°C.  A pulse of [3H]-Ang II was added to the 
donor chamber alone and samples were taken for 30 minutes from the receiver chamber.  After the 
initial 30 minutes, an unlabeled peptide was added to the donor chamber and the transport was 
followed for 60 additional minutes.  Samples were taken as described above.  The flux was determined 
by plotting pmoles versus minutes.  The apparent permeability coefficient was calculated using the 
equation described above. 
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Effect of Endocytic Inhibitors on [3H]-Angiotensin II Uptake and Transport 
The effect of selected endocytic inhibitors on [3H]-Ang II was studied on confluent monolayers 
grown in 24-well plates.  A pulse of [3H]-Ang II was added to each well along with µM concentrations of 
chloroquine, monensin, or phenylarsine oxide dissolved in culture medium containing serum.  The plates 
were incubated at 37°C for 90 minutes.  After the incubation, the monolayers were quickly rinsed three 
times with 4°C culture medium and solubilized as described above.  The lysate from each well was 
collected, placed in a scintillation vial with 10 ml of scintillation cocktail, and assayed with a Beckman LS 
6800 scintillation counter.  
The transport of a pulse of [3H]-Ang II alone was monitored for 30 minutes at 37°C as described 
above.  After the 30 minute sample was removed, an endocytic inhibitor (i.e., 25 µM chloroquine or 10 
µM monensin or 25 µM phenylarsine oxide) was added to the donor chamber and Ang II transport was 
followed for an additional 60 minutes.  Apparent permeability coefficients for Ang II in the presence of 
the inhibitor were calculated as described above. 
 
Statistical analysis 
 The comparison between mean values within each experimental series was performed by one-
way analysis of variance using Dunnett’s test to compare several treatments against a control. 
 
RESULTS 
Angiotensin II Uptake and Transendothelial Permeability  
Rose, J.M. and Audus, K.L. (1998) Receptor-mediated angiotensin II transcytosis by brain mcrovessel endothelial cells.  Peptides 
19, 1023-1030.  PMID: 9700750.  Publisher’s official version: <http://dx.doi.org/10.1016/S0196-9781(98)00054-0> .  Open 
Access version:  http://kuscholarworks.ku.edu/dspace/. 
8 
 
 Total Ang II binding and uptake reached an apparent plateau after 20 minutes (data not shown).  
The amount of Ang II internalized was found by subtracting the value at 4°C from the value at 37°C, 
giving a value of 1.4 x 10-12 moles (i.e., approximately 0.05% of the pulse) at 20 minutes, consistent with 
earlier work in our laboratory (12).   By contrast, the apical-to-basolateral permeation of Ang II across 
BMEC monolayers found to increase linearly with time over a two hour period.  Figure 1 shows the 
transport of Ang II at 4°C, 37°C, and across collagen-coated polycarbonate membranes in the absence of 
cells at 37°C.  The presence of the BMEC monolayer on the collagen-coated polycarbonate membrane 
illustrated the barrier formed by the cell systems to Ang II permeation.  The low temperature (4°C) 
reduced the transport of Ang II and represented any leakage of the peptide across the monolayers 
which was not due to cell mediated pathways.  By subtracting the 4°C data from the 37°C data the net 
permeability was found to be 5 x 10-5 cm/sec and represented the transcellular passage of Ang II.   The 
permeation of 3 nM [3H]-Ang II was also studied across BMEC monolayers in the basolateral-to-apical 
direction at 37°C and the apparent permeability coefficient was 3.5 x 10-5 cm/sec.  While not statistically 
significant, the trend of a 1.3 to 1.4 fold greater apical-to-basolateral permeation of Ang II across the 
monolayers was always reproducible. 
 The concentration dependence of Ang II transport in the apical-to-basolateral direction was 
performed at 37°C.  Similar data was collected at 4°C, was subtracted from the 37°C data, and the 
difference plotted as shown in Figure 2.  The resulting curve indicated that Ang II transport across BMEC 
monolayers was a saturable process with a Km of 1.7 nM.  At Ang II concentrations above the saturation 
point or plateau (>20 nM), peptide transport was found to again increase rapidly and linearly with 
increasing concentrations (data not shown). 
 
Effect of Unlabeled Angiotensin II Peptides on [3H]-Angiotensin II Internalization and Transport 
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 The effect of unlabeled Ang II on [3H]-Ang II transport is shown in Figure 3.  For these studies, a 
pulse of [3H]-Ang II was added to the donor chamber and samples were taken for 30 minutes.  After the 
30 minute sample, unlabeled Ang II or an equivalent amount of the peptide’s solvent (control) was 
added to the donor chamber and the receiver samples were taken for an additional 60 minutes.  A 
deflection in the slope was not observed for control experiments (Figure 3).  Figures 4A and 4B 
summarize the statistically significant inhibitory effects of unlabeled Ang II on [3H]-Ang II internalization 
by and permeation across BMEC monolayers.  Addition of  25 nM sarathrin ([Sar1,Thr8]-Ang II), a 
nonspecific angiotensin II peptide antagonist, also significantly inhibited Ang II apical-to-basolateral 
transport by approximately 30% (data not shown).  
As illustrated in Figure 5A, a 10 nM concentration of each of the Ang II fragments increased the 
transport of a pulse of [3H]-Ang II.  The effects seen with Ang II-(1-7) were not significant while both Ang 
II-(2-8), also known as angiotensin III, and Ang II-(3-8), also known as angiotensin IV, were shown to 
significantly increase the transport of Ang II across BMEC monolayers.  By contrast, internalization 
studies shown in Figure 5B indicated that only the Ang II-(1-7) fragment significantly enhanced Ang II 
uptake.  
 
Effect of Endocytic Inhibitors on [3H]-Angiotensin II Internalization and Transport 
 Figures 6A, 6B, and 6C show the effect of endocytic inhibitors on internalization of  [3H]-Ang II 
and apical-to-basolateral transport of the peptide by BMECs. Ang II internalization studies revealed that 
both monensin and phenylarsine oxide inhibited uptake of the peptide with monensin’s effects being 
statistically significant.   In transport studies, chloroquine (25µM) and monensin (10µM) had no 
significant effect on [3H]-Ang II permeation across BMEC monolayers.  However, 25µM phenylarsine 
oxide was shown to significantly decrease the apical-to-basolateral transport of  [3H]-Ang II. 
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DISCUSSION 
 The characterization of the internalization and transcytosis of endogenous peptide hormones by 
brain microvessel endothelium can provide a fundamental understanding of the role of peptide 
transporters at the BBB and the significance of these transport processes in regulating circulating levels 
of vasoactive peptides in the cerebrovasculature. Our primary objective here was to use an in vitro 
system to develop an understanding of the mechanisms by which circulating Ang II concentrations are 
regulated and cleared by the endothelial lining of the cerebrovasculature.  
 The rate of passage of Ang II across the BMEC monolayers was greater than would be predicted 
on the basis of molecular weight and comparable to an inert, low molecular weight passive, paracellular 
permeability marker, sucrose. The apical-to-basolateral transport of  [3H]-Ang II across BMEC 
monolayers was also found to be linear and more rapid than passage of the peptide from the 
basolateral-to-apical side of the cells.  The relative asymmetry of the permeation of the peptide across 
the monolayers was consistent with our earlier studies which demonstrated that permeability regulation 
by Ang II was largely due to an apical membrane associated process (13).   Further, the relative polarity 
of Ang II permeation was consistent with BBB’s tendency of a reduced endocytic capability at the 
abluminal (brain) surface (9) and in good agreement with in vitro Ang II processing by peripheral 
endothelia (18) and proximal tubule epithelia where the peptide’s transport was found to be relatively 
asymmetric and transcellular in nature (6).  
The apical-to-basolateral permeation of Ang II across BMEC monolayers was concentration-
dependent and saturable with an apparent Km of 1.7 nM.  The affinity of the carrier is in line with the 
specific binding Kd of 3.1 nM for the cells determined in our laboratory (12) and the 1.22 nM Kd reported 
by Speth and Harik (30) for Ang II binding to canine microvessels. In the earlier work, we demonstrated 
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that Ang II exposure (i.e., 1 to 100 nM) produced a concentration-dependent decrease in the 
permeability of paracellular markers, fluorescein, molecular weight 376, and a fluorescein 
isothiocyanate-conjugated dextran, molecular weight of 4000 (13).  Therefore, while the flux of Ang II 
itself increases with increasing concentration, the paracellular permeability of the monolayers decreases 
with increasing concentration of the peptide.    Therefore, we believe we have established that Ang II 
processing across BMEC monolayers occurred through a transcellular pathway. 
Saturable, receptor-mediated endocytosis of Ang II has now been described in a number of cell 
types (6,17,19,34,35).   Specifically in endothelia, the absence of  significant degradation of internalized 
Ang II has now been confirmed by both in vitro and in vivo studies.  In our laboratory, three separate 
analytical systems, TLC (12), HPLC with electrochemical detection (28), and HPLC with fluorescence 
detection (2), have demonstrated that Ang II remains intact under the conditions of both the 
internalization and transport studies described in this report.  Reports for peripheral endothelia (18) and 
proximal tubule epithelia (6) have also provided observations on the saturable transcellular transport of 
intact Ang II.  However, these in vitro observations also fully support the recent van Kats et al. (35) 
report which indicated that in vivo, endothelial cell clearance of Ang II through an AT1 receptor-
mediated process seems to serve to protect the peptide from endothelial cell peptidases.  
The uptake and transport of radiolabeled Ang II was found to be significantly inhibited by the 
addition of nM concentrations of unlabeled Ang II or the Ang II peptide antagonist sarathrin.   These 
findings were in good agreement with similar studies with other cell types (6,17-19,34,36). At 
concentrations above the plateau (>20 nM),  we observed Ang II transport to increase linearly with 
increasing concentrations (data not shown).  This phenomenon is seen with many receptor-mediated 
endocytic processes where the molecule exhibits an affinity for the endothelial plasma membrane (37).  
At lower concentrations, the molecule will exhibit endocytic rates that are dependent upon the number 
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of membrane binding sites, the dissociation constant of these sites, and the rate of ingestion of surface 
membrane.  As the concentration increases the binding sites become saturated and the rate of 
endocytosis reaches a steady state.  At higher concentrations of substrate, the fluid-phase endocytosis 
component appears thus showing a linear relationship (37).  We can not rule out some contributions of 
fluid-phase endocytosis to Ang II uptake and transcellular permeation, as our lab and others have 
demonstrated an Ang II-induced fluid-phase endocytosis in bovine (11) and human (31) BMECs.   We 
suppose this nonspecific transport may in fact contribute to the absence of complete inhibition of Ang II 
internalization and transport in the presence of peptide competitors for receptor binding.  
  In vivo in the circulation, Ang II is likely to be metabolized and fragments of the peptide can 
interact with receptor sites. Thus, we examined effects of three prominent fragments on Ang II uptake 
and transport.   The three fragments of Ang II, Ang II-(1-7), Ang III, and Ang IV, all increased the 
transcellular transport of Ang II across BMEC monolayers.  Only Ang II -(1-7) significantly increased the 
internalization of the parent peptide.  Currently, there are four Ang II receptor populations that have 
been described (16,29,32).  Most of the known biological activities of Ang II are believed to be mediated 
by the AT1 receptor (33).  Ang II-(1-7) has been shown to have effects that are opposite of Ang II, 
including inhibition of vasoconstriction and cell growth, which do not appear to be mediated by either 
the AT1 or AT2 receptor (10,20,21).  Ang II-(2-8) is reported to have activity as a vasoconstrictor, 
presumably through the AT1 receptor (29).  The AT4 receptor, which preferentially binds Ang II-(3-8), has 
been implicated in memory acquisition and retrieval, and the regulation of blood flow (39).  Ang II-(3-8) 
and Ang II were found to have opposite effects on cerebral blood flow, with Ang II decreasing blood flow 
and Ang II-(3-8) increasing blood flow (16).  Ang II-(3-8) was also implicated as a vasodilator in rat 
cerebral arteries (15).   Considering the disparate actions and affinities of the Ang II fragments for the 
AT1 receptor, we suggest that the internalization and transport process we observed here were specific 
to the parent Ang II and the AT1 receptor.  In part this supposition is based on our recent work (27) 
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which demonstrated that an AT2 antagonist did not inhibit the permeation of Ang II across the BMEC 
monolayers.  That work also established with immunoblots, expression of a membrane-associated AT1 
receptor (27).  Unfortunately, antibodies do not currently exist for the other receptors.   The Ang II 
fragments may either interact with other binding sites that indirectly regulate endocytic processes of 
BMECs or, alternatively, the fragments may displace Ang II from other non-AT1 binding sites, providing 
more Ang II for specific internalization or transport pathways.  Future work will be directed at defining 
the role of the fragments in binding, controlling fluid-phase endocytosis, and other biological functions 
in the BMECs. 
Receptor-mediated endocytosis and transcytosis as mechanisms for Ang II processing by BMECs 
was supported by our observations that known endocytic inhibitors, monensin and phenylarsine oxide 
both inhibited Ang II internalization by BMECs.  Phenylarsine oxide also significantly inhibited the 
transport of Ang II across the BMEC monolayers while monensin and chloroquine had little or no effect 
on peptide transport. Phenylarsine oxide has been shown to consistently inhibit, at least in part, Ang II 
internalization and transport in other studies (6,17) and was supported by our observations.  Monensin 
has been shown to effectively inhibit Ang II AT1 receptor internalization and recycling back to the cell 
surface (17,26) and chloroquine inhibits Ang II dissociation from cells (17).   We did not look at Ang II 
return to the culture medium in this study and chloroquine may, in fact, have had effects on this process 
by BMECs.  We did previously find that chloroquine inhibited Ang II-stimulated fluid-phase endocytosis 
by BMECs (11) and may be an indication that only certain endosomal pathways of these cell were 
sensitive to the drug. Although the concentrations of inhibitors used here were within ranges known to 
affect the internalization and transport of other receptors, the effects of these inhibitors generally differ 
from cell type to cell type.  From earlier work we also know that the activity of apical membrane 
internalization-recycling activities by BMECs appeared to be quite active while the contributions of 
transcellular transport were limited (14,23).  The differences between effects of the endocytic inhibitors 
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on internalization and transport could also be due to the differences between experimental conditions 
in uptake and transport studies.  For the internalization studies, Ang II and the inhibitors were added at 
the same time whereas in the more dynamic transport studies, the inhibitor was added after Ang II was 
already being processed for transcytosis by the BMECs.  Therefore, in the transport studies the more 
active internalization process allowed Ang II to enter the cell and the intracellular sorting process.  
Consequently, much of the Ang II transport observed in the presence of the inhibitors was peptide that 
may have entered the cells prior to addition of the agent.   Irregardless, the sensitivity of the 
internalization and transport of Ang II to monensin and phenylarsine oxide affirmed a role for 
endosomal processing of the peptide and was consistent with reports for other cell types exhibiting 
receptor-mediated endocytosis (17-19,34,36).    
 In conclusion, the permeation of Ang II across BMEC monolayers was linear, concentration-
dependent, saturable, tended to be polarized in the apical-to-basolateral direction, and was attenuated 
by endocytic inhibitors.  This study forms the basis to further consider metabolically stable Ang II 
peptide analogs or Ang II receptor substrates as BBB transport vectors and further supports the role of 
the BBB as an active participant in regulating vascular levels of peptide hormones.   
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FIGURE LEGENDS 
 
FIG. 1.  Permeation of Ang II across brain microvessel endothelial cell monolayers.  Transport was 
studied on membranes without cell monolayers and on cell monolayers at 4°C and 37°C.  A 
concentration of 3 nM [3H]-Ang II was used in each donor chamber.  Each data point represents the 
mean ± SD (n = 3). 
 
FIG. 2.  Concentration dependence of Ang II flux across brain microvessel endothelial cells in the apical-
to-basolateral direction.  The data points represent the net permeation (the difference between 37°C 
and 4°C data) for Ang II across the BMEC monolayers.  Each data point represents the mean difference 
from triplicate experiments at 4°C and 37°C. 
 
FIG. 3.  [3H]-Ang II permeation across brain microvessel endothelial cells at 37°C.  After monitoring the 
passage of [3H]-Ang II across the monolayers for 30 minutes, unlabeled Ang II or the peptide’s solvent 
(control) was added to the donor chamber as a competitor and data was collected for an additional 60 
minutes as shown.   Control data is represented by the solid line. 
 
FIG. 4. A) Angiotensin II uptake (pulse of [3H]-Ang II) in brain microvessel endothelial cells alone (shaded 
bar) and in the presence of nM concentrations of unlabeled Ang II (hatched bars) for 45 minutes at 37°C, 
pH 7.4.  Each bar represents the mean ± SD (n = 4).  * represents statistically significant changes (P < 
0.05).  B) Apparent permeability coefficients for a pulse of [3H]-Ang II alone (shaded bar) and in the 
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presence of unlabeled Ang II (hatched bars) across brain microvessel endothelial cells.  Each bar 
represents the mean ± SD (n = 3).  * Statistically significant changes (P < 0.05).  ** Statistically significant 
changes (P < 0.01). 
 
FIG. 5.  A) Angiotensin II uptake (pulse of [3H]-Ang II) in brain microvessel endothelial cells alone (shaded 
bar) and in the presence of 10 nM Ang II-(1-7), 10 nM Ang II-(2-8), or 10 nM Ang II-(3-8) (hatched bars) 
for 45 minutes at 37°C, pH 7.4.  Each bar represents the mean ± SD (n = 4).  * represents statistically 
significant changes (P < 0.05).  
 B) Apparent permeability coefficients for a pulse of [3H]-Ang II alone (shaded bar) and in the presence of 
10 nM Ang II-(1-7), 10 nM Ang II-(2-8), or 10 nM Ang II-(3-8)  (hatched bars) across brain microvessel 
endothelial cells.  Each bar represents the mean ± SD (n = 3).  ** Statistically significant changes (P < 
0.01). 
 
FIG. 6. A)  Percentage of [3H]-Ang II uptake in brain microvessel endothelial cells alone (shaded bar) and 
in the presence of µM concentrations of monensin (hatched bars) for 90 minutes at 37°C, pH 7.4.  Each 
bar represents the mean ± SD (n = 4).  * represents statistically significant changes (P < 0.05); ** 
represents statistically significant changes (P < 0.01).  B) Percentage of [3H]-Ang II uptake in brain 
microvessel endothelial cells alone (shaded bar) and in the presence of µM concentrations of 
phenylarsine oxide (hatched bars) for 90 minutes at 37°C, pH 7.4.  Each bar represents the mean ± SD (n 
= 4). * represents statistically significant changes (P < 0.05).  C)   Apparent permeability coefficients for a 
pulse of [3H]-Ang II alone (shaded bar) and in the presence of 25 µM chloroquine, 10 µM monensin, or 
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25 µM phenylarsine oxide (hatched bars) across brain microvessel endothelial cells.  Each bar represents 
the mean ± SD (n = 3).  ** Statistically significant changes (P < 0.01). 
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